Tissue Therapies Limited is a heath biotechnology company that develops and manufactures synthetic proteins for wound healing applications.
Tissue Therapies Limited is commercialising VitroGro® ECM for the treatment of venous leg ulcers and diabetic foot ulcers. VitroGro®is a broad spectrum healing promoter for the treatment of ulcers of all severity.
Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.
Tissue Therapies Limited has identified that there is a significant need in wound care for improving the outcome of hard to heal wounds. Hard to heal wounds are defined as wounds that have not respond to standard therapy in an orderly and timely manner . This type of delayed healing occurs in a variety of wound types (venous leg ulcers, arterial leg ulcers, mixed leg ulcers, diabetic foot ulcers and pressure ulcers)
VitroGro® ECM is a new treatment for hard to heal wounds that is used in conjunction with standard care including moist wound dressing and compression. We see opportunities to have significant impact in wound care markets in Asia, Australia, Canada, Europe, New Zealand, the United States and other markets experiencing the economic burden of wound care.
ASX Listing: TIS